Radiopharm Theranostics RADX
NASDAQ RADX
$0.88 -0.07 (-7.70%)
At close: Nov 9, 2026 · 4:00 PM EST

Radiopharm Theranostics (RADX) Total Non-Current Liabilities (2024 - 2026)

Updated

Radiopharm Theranostics (RADX) reported Total Non-Current Liabilities of $134,159 for fiscal Q4 2026 (quarter ended Jun 30, 2026), down 27.0% from $183,657 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics posted Total Non-Current Liabilities of $128,449, down 99.6% from FY2025.

  • By fiscal year, Total Non-Current Liabilities came in at $28.68 million in FY2025 (+5.8%) and $27.11 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn 60.81 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn 102.65 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn 117.60 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn 79.95 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn -36.84 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn 76.12 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn 36.05 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn 96.04 Bn
10 Radiopharm Theranostics 2.70 Bn 2.62 Bn - 18.91 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 18.91 Mn
Jun 30, 2025 28.68 Mn
Dec 31, 2024 27.30 Mn
Jun 30, 2024 27.11 Mn
API Access

Radiopharm Theranostics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=RADX&period=max&api_key=YOUR_API_KEY